What's New Archive

ROZLYTREK™ (entrectinib) is now FDA approved


Merck is pleased to announce that KEYTRUDA


Pfizer Oncology is proud to announce that the indications for IBRANCE


NCCN© has updated the Clinical Practice Guidelines


New combination now approved for CLL


Permanent J-codes for Genentech Hematology Products


Announcing a New First-Line Indication for a Genentech Therapy


New indication for VENCLEXTA® (venetoclax tablets)


XOSPATA Is the First FDA-Approved FLT3 Inhibitor Indicated for Patients with Relapsed or Refractory FLT3m+ Acute Myeloid Leukemia (AML)1


NEW PRODUCT ANNOUNCEMENT


New MAC for NJ announced

Highmark is the new MAC for PA, NJ, DE, MD & DC.
Additional information


ASP Update on Aranesp

by Sandy Victor

If you use Aranesp, Medicare adjusted the ASP for all 3 previous quarters of 2007 as of October 1st.


Aloxi Documents


NPPES and the NPI Registry

Many of you have noted the recent instability of NPPES and the NPI Registry. CMS has begun implementing changes that should eliminate the instability. We expect that these changes will be completed next week.


New Diagnosis Codes

Important: There is NO GRACE period for the new Diagnosis codes. The New Diagnosis Codes are effective 10/01/2007.


FDA Approval of Vidaza NDA Supplement for IV Administration

Click Here


DMERC Oral Anti-cancer Drugs


United Healthcare/Oxford

Patients must use LabCorp Laboratories or a local hospital that is participating with the plans. DO NOT USE QUEST EFFECTIVE 01/01/2007.


Herceptin Coverage


Expanded Coverage of Bevacizumab (Avastin )


New FDA Approval for Gemzar in Ovarian Cancer

approval April 2006


Reimbursement Hotlines 2005


IMPORTANT

The information provided by NJSOM through our meetings or website is for educational purposes only. NJSOM is not responsible for implementation and or suggesting what should be done in your practice. All information provided should be reviewed and assessed by each individual practice.